Antibody drug conjugates: Progress, pitfalls, and promises.

Area of Science:

• Oncology
• Immunology
• Pharmacology

Background:

• Antibody drug conjugates (ADCs) are an effective targeted cancer therapy.
• ADCs comprise a monoclonal antibody, a cytotoxic drug, and a linker for tumor selectivity.
• Recent approvals have spurred significant research, with over 60 ADCs in clinical development.

Purpose of the Study:

• To review the key components in designing antibody drug conjugates.
• To discuss improvements and lessons learned in ADC research over two decades.
• To explore the future of third-generation ADCs.

Main Methods:

• Literature review of antibody drug conjugate research.
• Analysis of ADC design principles and components.
• Examination of historical data and future trends in ADC development.

Main Results:

• ADCs provide targeted delivery, reduced toxicity, and enhanced stability.
• Successful ADC design relies on specific antigen selection and optimized components.
• Ongoing research focuses on overcoming challenges and advancing ADC technology.

Conclusions:

• Antibody drug conjugates are a vital tool in targeted cancer therapy.
• Continued research and careful design are crucial for the success of future ADCs.
• The evolution of ADCs, including third-generation therapies, promises improved cancer treatment outcomes.